A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS 5734TM) in Participants with Moderate COVID 19 Compared to Standard of Care Treatment (GS US 540 5774)

Gender
Any

Age Group
Any

At a Glance

IRB#IRB20-0433

Lead PhysicianKathleen Mullane

Collaborator(s)N/A

EligibilityNot Recruiting